Analyst Price Target is $54.57
▲ +184.82% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $54.57, with a high forecast of $93.00 and a low forecast of $46.00. The average price target represents a 184.82% upside from the last price of $19.16.
Current Consensus is
The current consensus among 6 investment analysts is to buy stock in Protagonist Therapeutics. This Buy consensus rating has held steady for over two years.
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.